According to the World Health Organization there are about 250,000 new cases of prostate cancer every year but, when caught in time, the disease has a cure rate of over 90%. The problem is that the current methods of disease testing are still associated with too many misdiagnoses. Now however, research by Portuguese and Norwegian scientists, just published on the journal Clinical Cancer Research ¹   describes, not only how whole genome analysis can help to increase the accuracy of patient testing, but also identifies a new molecular marker that “tags” prostate cancers with worse prognoses These results have important implications for the clinical management of patients as they will allow, together with standard methods of cancer analysis, better informed therapeutic measures.

*  "This article is the result of a project for the divulgation of portuguese science" http://www.cienciahoje.pt/1455"